about PharmaEngine

PharmaEngine focuses on the development of new medications for the treatment of cancer and Asian prevalent diseases. PharmaEngine has three development projects: PEP02 (MM-398, ONIVYDE) is approved by the TFDA and U.S. FDA and under the NDA review by the EMA; PEP503 (NBTXR3) in a global pivotal trial of soft tissue sarcoma; and PEP06 in lead optimization.